Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhengqingfengtongning extended-release tablets for IgA nephropathy
ChiCTR-IIR-17013487Phase 4Recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Dec 2017
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sinomenine and losartan in IgA nephropathy (IgAN) (3 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: 24-hour urinary protein quantification. Started Dec 2017; status: recruiting.
02
Drugs
sinomeninelosartan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR-IIR-17013487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013487.